Xeris Biopharma Holdings, Inc.
XERSNASDAQHealthcareBiotechnology
Previous close
$8.70
+$0.10 · +1.16%
XERS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
87
Deep Value
Momentum
61
Gaining
Sentiment
50
Mixed
Risk resilience
62
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteXeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- John Shannon
- Listed since
- Jun 21, 2018
- Employees
- 435
Market position
Day range
Current $8.70
52-week range
Current $8.70
- Open
- $8.63
- Previous close
- $8.60
- Volume
- 1.56M
- 0.86× average
- Average volume
- 1.81M
- Average daily volume
- Market cap
- 1.5B USD
- Beta
- 0.85
- Market reference 1
- 50-day average
- $8.0848
- +7.61% above average
- 200-day average
- $7.0119
- +24.07% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.19B USD
- P/E (TTM)
- -89.6×
- P/B (TTM)
- -154.47×
- P/S (TTM)
- 4.48×
- EV / EBITDA
- 93.32×
- Earnings yield
- 0.04%
- Free cash flow yield
- 2.22%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 83.34%
- Operating margin
- 10.91%
- Net margin
- -5.12%
- Return on equity
- 4.05%
- Return on assets
- 0.14%
- Return on invested capital
- 8.89%
Financial health
- Debt / equity
- -29.74×
- Current ratio
- 2.19×
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -84.06%
- 11 comparable reports
- Latest EPS result
- -0.18
- Estimate 0.01 · Miss by 1582.70%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$12.00
37.93% upsideXERS peers
ETFs holding XERS
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI41.96M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM37.73M0.05%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF16.07M0.02%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO13.61M0.09%15.16B USD0.24%$387.37+1.24%
First Trust Small Cap Growth AlphaDEX FundFYC8.11M0.58%1.42B USD0.70%$122+0.71%
State Street SPDR S&P Pharmaceuticals ETFXPH7.91M1.41%560.87M USD0.35%$72.80+0.71%
Vanguard Russell 2000 ETFVTWO7.77M0.04%17.4B USD0.06%$121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA7.06M0.03%23.1B USD0.03%$34.83+0.52%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 41.96M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 37.73M
- Weight
- 0.05%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 16.07M
- Weight
- 0.02%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 13.61M
- Weight
- 0.09%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
First Trust Small Cap Growth AlphaDEX FundFYC- Market value
- 8.11M
- Weight
- 0.58%
- AUM
- 1.42B USD
- Expense ratio
- 0.70%
- Price / 1D
- $122+0.71%
State Street SPDR S&P Pharmaceuticals ETFXPH- Market value
- 7.91M
- Weight
- 1.41%
- AUM
- 560.87M USD
- Expense ratio
- 0.35%
- Price / 1D
- $72.80+0.71%
Vanguard Russell 2000 ETFVTWO- Market value
- 7.77M
- Weight
- 0.04%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 7.06M
- Weight
- 0.03%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Continue in GoAI
Research XERSresearch.disclaimer